Table 2c.
The relationship between composite ratios and cumulative scores and their component values in patients undergoing surgery for colon cancer (n = 801)
| n (%) | Median (range) | Median (range) | |
|---|---|---|---|
| Neutrophil | Lymphocyte | ||
| NLR | |||
| ≤3 | 388 (48.4) | 4.2 (0.4–9.0) | 2.0 (0.7–14.1) |
| 3–5 | 260 (32.5) | 5.5 (2.1–17.5) | 1.5 (0.5–4.7) |
| >5 | 153 (19.1) | 8.5 (2.2–21.3) | 1.1 (0.3–2.5) |
| NLS | |||
| 0 | 421 (52.6) | 4.8 (1.7–7.5) | 2.0 (1.5–14.1) |
| 1 | 325 (40.6) | 5.1 (0.4–20.6) | 1.3 (0.3–4.70) |
| 2 | 55 (6.9) | 9.9 (7.6–21.3) | 1.1 (0.5–1.4) |
| Platelet | Lymphocyte | ||
| PLRa | |||
| ≤150 | 237 (34.8) | 248 (93–653) | 2.1 (1.0–14.1) |
| >150 | 445 (65.2) | 325 (119–814) | 1.40 (0.30–4.70) |
| PLSa | |||
| 0 | 351 (51.5) | 282 (94–396) | 2.0 (1.5–14.1) |
| 1 | 283 (41.5) | 292 (93–814) | 1.3 (0.3–11.0) |
| 2 | 48 (7.0) | 478 (406–698) | 1.1 (0.6–1.4) |
| Lymphocyte | Monocyte | ||
| LMRb | |||
| ≥2.4 | 252 (61.0) | 1.9 (0.6–14.1) | 0.6 (0.1–1.3) |
| <2.4 | 161 (39.0) | 1.3 (0.3–3.0) | 0.8 (0.3–2.0) |
| LMSb | |||
| 0 | 214 (51.8) | 2.0 (1.5–14.1) | 0.6 (0.1–0.8) |
| 1 | 169 (40.9) | 1.3 (0.3–4.6) | 0.7 (0.1–2.0) |
| 2 | 30 (7.3) | 1.2 (0.6–1.4) | 1.0 (0.9–1.9) |
| Neutrophil | Platelet | ||
| NPSa | |||
| 0 | 491 (72.0) | 4.5 (0.4–7.50) | 268 (93–400) |
| 1 | 140 (20.5) | 6.7 (2.3–18.8) | 415 (96–811) |
| 2 | 51 (7.5) | 9.8 (7.6–20.60) | 474 (406–814) |
| CRP | Albumin | ||
| CAR | |||
| ≤0.22 | 412 (51.4) | 5 (0.1–9) | 38 (21–49) |
| >0.22 | 389 (48.6) | 22 (6–339) | 35 (15–47) |
| mGPS | |||
| 0 | 474 (59.2) | 5 (0.1–10) | 38 (21–49) |
| 1 | 173 (21.6) | 22 (11–220) | 38 (35–47) |
| 2 | 154 (19.2) | 37 (11–339) | 31 (15–34) |
an = 682.
bn = 413.
NLR neutrophil–lymphocyte ratio, NLS neutrophil–lymphocyte score, CAR C-reactive protein albumin ratio, mGPS modified Glasgow prognostic score, NPS neutrophil–platelet score, LMS lymphocyte–monocyte score, LMR lymphocyte–monocyte ratio, PLR platelet–lymphocyte ratio, PLS platelet–lymphocyte score